Oscotec

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • Foreign exchange risk arises from recognized assets and liabilities denominated in non-functional currencies
• • Foreign exchange risk managed via currency forward contracts when hedging deemed necessary

Business Overview

• • Core revenue from synthetic new drug licensing milestone KRW 89.1B (89.3% of total sales) in FY2025
• • Alzheimer’s disease antibody ADEL-Y01 licensed to global pharma Dec 2025, FDA clinical phase 1 ongoing

Management Discussion & Analysis

• • Revenue KRW 99,838M (+193.58% YoY), Operating profit KRW 52,081M, Net profit KRW 54,397M, all turned positive vs loss prior year
• • Biggest driver: Technology transfer revenue increased 222.70% to KRW 89,144M due to overseas milestone from lung cancer drug Lezatinib and contract for Adel-Y01

What are the latest Oscotec DART filings in 2026?

Oscotec (KRX code 039200) has filed an annual report on March 19, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Oscotec file its most recent annual report?

Oscotec filed its most recent annual report on March 19, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Oscotec's KRX stock code?

Oscotec's KRX stock code is 039200. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 039200 to look up all Oscotec disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Oscotec file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Oscotec.

Where can I find Oscotec financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Oscotec annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.